Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 29
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/8/2008
 
First Published:
3/24/2003
1.
Phase III Randomized Study of Preoperative Chemoradiotherapy Comprising Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin in Patients With Resectable Rectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
NSABP-R-04
NCT00058474, NSABP-R-04, CALGB-NSABP-R-04
Last Modified:
10/10/2008
 
First Published:
3/13/2006
2.
Phase III Randomized Study of Adjuvant Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Bevacizumab in Patients Who Have Undergone Surgery and Neoadjuvant Chemoradiotherapy for Stage II or III Rectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
ECOG-E5204
E5204, NSABP-ECOG-E5204, NCCTG-ECOG-E5204, NCT00303628
3.
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
05-345
NCT00307736
4.
Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
2007-0080
NCT00543842
Last Modified:
10/2/2008
 
First Published:
9/16/2008
5.
Phase I/II Randomized Study of Erlotinib Hydrochloride in Inhibiting Epidermal Growth Factor Receptor Signaling in Aberrant Crypt Foci in Patients With Curatively Treated Stage I-III Colorectal Cancer or Adenoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
Not specified
NCI
UCIRVINE-UCI06-8-01
UCI06-8-01, NCT00754494
6.
Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
HOG GI03-53
NCT00216086
7.
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
3304C
NCT00250835
Last Modified:
9/29/2008
 
First Published:
2/3/2006
8.
Phase II Study of Neoadjuvant Chemoradiotherapy Comprising Radiotherapy and Fluorouracil With or Without Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil Followed By Surgical Resection in Patients With Stage II or III Rectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
UCSF-03451
UCSF-H44287-23127-03, NCT00335816, UMN-2003UC036
9.
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage I/II Rectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
SCRI GI 65
AVF3105s, NCT00308516
10.
Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
803437
UPCC 09204, NCT00353457
Select All on One Page
1
2
3
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute